scholarly journals Impact of Metabolic Syndrome Components in High-Risk Cardiovascular Disease Development in Older Adults

2020 ◽  
Vol Volume 15 ◽  
pp. 1691-1700
Author(s):  
Yuri Gustavo de Sousa Barbalho ◽  
Marina Morato Stival ◽  
Luciano Ramos de Lima ◽  
Izabel Cristina Rodrigues da Silva ◽  
Alessandro de Oliveira Silva ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Older Adults ◽  
Metabolic Syndrome ◽  
High Risk ◽  
Disease Development ◽  
Metabolic Syndrome Components

scholarly journals Sex differences in metabolic syndrome components in adolescent military dependents at high‐risk for adult obesity

2020 ◽  
Vol 15 (8) ◽  
Author(s):  
Lisa M. Shank ◽  
M. Katy Higgins Neyland ◽  
Jason M. Lavender ◽  
Rachel Schindler ◽  
Senait Solomon ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Sex Differences ◽  
High Risk ◽  
Adult Obesity ◽  
Military Dependents ◽  
Metabolic Syndrome Components

Metabolic syndrome and diabetes

2019 ◽  
pp. 49-58
Author(s):  
Christoph H. Saely
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Primary Prevention ◽  
High Risk ◽  
Cardiovascular Events ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Patients With Diabetes ◽  
Multifactorial Approach ◽  
Very High

The metabolic syndrome (MetS) and even more so diabetes confer a significantly increased risk of cardiovascular disease. A multifactorial approach is required to improve the prognosis of patients with the MetS or diabetes. Glucose control is essential to reduce microvascular diabetes complications and, over long periods of time, may also lower the risk of cardiovascular events in patients with diabetes. As in other patient populations, lowering low-density lipoprotein (LDL) cholesterol and treating arterial hypertension are paramount interventions to reduce cardiovascular event risk in patients with the MetS and diabetes. Most patients with diabetes must be considered at a very high risk of cardiovascular events, which qualifies them for low LDL cholesterol targets. Antiplatelet therapy is recommended for patients with the MetS or diabetes in secondary prevention; it may also be considered for primary prevention patients with diabetes who are at high or very high risk; it is not recommended for primary prevention in diabetes patients at moderate risk. Because the MetS or diabetes confers an extremely high risk of cardiovascular events once cardiovascular disease is established, it is extremely important to intervene early to prevent these patients from developing cardiovascular disease.

Metabolic syndrome and diabetes

2019 ◽  
pp. 49-58
Author(s):  
Christoph H. Saely
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
High Risk ◽  
Cardiovascular Events ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
The Metabolic Syndrome ◽  
Patients With Diabetes ◽  
Multifactorial Approach

The metabolic syndrome (MetS) and even more so diabetes confer a significantly increased risk of cardiovascular disease. A multifactorial approach is required to improve the prognosis of patients with the MetS or diabetes. Glucose control is essential to reduce microvascular diabetes complications and, over long periods of time, may also lower the risk of cardiovascular events in patients with diabetes. As in other patient populations, lowering low-density lipoprotein (LDL) cholesterol and treating arterial hypertension are paramount interventions to reduce cardiovascular event risk in patients with the MetS and diabetes. Most patients with diabetes must be considered at a very high risk of cardiovascular events, which qualifies them for low LDL cholesterol targets. An-tiplatelet therapy is recommended for patients with the MetS or diabetes who already have established cardiovascular disease. Because the MetS or diabetes confers an extremely high risk of cardiovascular events once cardiovascular disease is established, it is extremely important to intervene early to prevent these patients from developing cardiovascular disease.

scholarly journals The Role of Sarcopenic Obesity in Cancer and Cardiovascular Disease: A Synthesis of the Evidence on Pathophysiological Aspects and Clinical Implications

2021 ◽  
Vol 22 (9) ◽  
pp. 4339
Author(s):  
Erika Aparecida Silveira ◽  
Rômulo Roosevelt da Silva Filho ◽  
Maria Claudia Bernardes Spexoto ◽  
Fahimeh Haghighatdoost ◽  
Nizal Sarrafzadegan ◽  
...  
Keyword(s):  
Public Health ◽  
Cardiovascular Disease ◽  
Older Adults ◽  
High Risk ◽  
Sarcopenic Obesity ◽  
Health Concern ◽  
Clinical Implications ◽  
Public Health Concern ◽  
Epidemiological Evidence

Obesity is globally a serious public health concern and is associated with a high risk of cardiovascular disease (CVD) and various types of cancers. It is important to evaluate various types of obesity, such as visceral and sarcopenic obesity. The evidence on the associated risk of CVD, cancer and sarcopenic obesity, including pathophysiological aspects, occurrence, clinical implications and survival, needs further investigation. Sarcopenic obesity is a relatively new term. It is a clinical condition that primarily affects older adults. There are several endocrine-hormonal, metabolic and lifestyle aspects involved in the occurrence of sarcopenic obesity that affect pathophysiological aspects that, in turn, contribute to CVD and neoplasms. However, there is no available evidence on the role of sarcopenic obesity in the occurrence of CVD and cancer and its pathophysiological interplay. Therefore, this review aims to describe the pathophysiological aspects and the clinical and epidemiological evidence on the role of sarcopenic obesity related to the occurrence and mortality risk of various types of cancer and cardiovascular disease. This literature review highlights the need for further research on sarcopenic obesity to demonstrate the interrelation of these various associations.

Sign in / Sign up

Export Citation Format

Share Document